Cigna Group $CI Stake Lessened by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS decreased its position in shares of Cigna Group (NYSE:CI) by 5.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 168,523 shares of the health services provider’s stock after selling 10,500 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Cigna Group were worth $48,577,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Wilsey Asset Management Inc. increased its position in Cigna Group by 2.9% in the 2nd quarter. Wilsey Asset Management Inc. now owns 101,936 shares of the health services provider’s stock worth $33,698,000 after purchasing an additional 2,847 shares during the last quarter. SCS Capital Management LLC lifted its holdings in shares of Cigna Group by 39.1% during the 2nd quarter. SCS Capital Management LLC now owns 30,633 shares of the health services provider’s stock valued at $10,127,000 after buying an additional 8,609 shares during the last quarter. Retirement Systems of Alabama grew its stake in shares of Cigna Group by 3.9% in the 2nd quarter. Retirement Systems of Alabama now owns 165,487 shares of the health services provider’s stock valued at $54,707,000 after buying an additional 6,155 shares in the last quarter. Modern Wealth Management LLC increased its holdings in Cigna Group by 91.3% in the first quarter. Modern Wealth Management LLC now owns 3,130 shares of the health services provider’s stock worth $1,030,000 after buying an additional 1,494 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its holdings in Cigna Group by 3.9% in the second quarter. Janney Montgomery Scott LLC now owns 35,943 shares of the health services provider’s stock worth $11,882,000 after buying an additional 1,357 shares during the last quarter. 86.99% of the stock is currently owned by institutional investors and hedge funds.

Cigna Group Trading Up 0.3%

Shares of CI opened at $284.77 on Wednesday. The stock’s 50-day moving average price is $271.29 and its 200 day moving average price is $289.50. The company has a quick ratio of 0.76, a current ratio of 0.76 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $76.07 billion, a price-to-earnings ratio of 12.56, a P/E/G ratio of 1.00 and a beta of 0.26. Cigna Group has a 12-month low of $239.51 and a 12-month high of $350.00.

Cigna Group (NYSE:CI) last posted its quarterly earnings results on Thursday, October 30th. The health services provider reported $7.83 earnings per share for the quarter, topping analysts’ consensus estimates of $7.64 by $0.19. The firm had revenue of $69.57 billion for the quarter, compared to the consensus estimate of $66.40 billion. Cigna Group had a net margin of 2.29% and a return on equity of 18.80%. The business’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $7.51 earnings per share. Cigna Group has set its FY 2025 guidance at 29.600- EPS. As a group, research analysts predict that Cigna Group will post 29.77 earnings per share for the current year.

Cigna Group Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Thursday, December 4th were given a $1.51 dividend. This represents a $6.04 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Thursday, December 4th. Cigna Group’s dividend payout ratio is 26.64%.

Analyst Ratings Changes

Several analysts have commented on the stock. Wells Fargo & Company decreased their target price on shares of Cigna Group from $354.00 to $300.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 5th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Cigna Group from $415.00 to $301.00 and set a “buy” rating for the company in a report on Monday, November 3rd. Zacks Research upgraded Cigna Group from a “strong sell” rating to a “hold” rating in a report on Monday. Guggenheim reaffirmed a “buy” rating and issued a $318.00 price target on shares of Cigna Group in a research report on Tuesday, December 2nd. Finally, Barclays increased their price objective on Cigna Group from $300.00 to $305.00 and gave the company an “overweight” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $333.04.

Insider Transactions at Cigna Group

In other Cigna Group news, CEO David Cordani purchased 4,134 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was purchased at an average price of $241.88 per share, for a total transaction of $999,931.92. Following the completion of the purchase, the chief executive officer directly owned 157,935 shares in the company, valued at approximately $38,201,317.80. This trade represents a 2.69% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.70% of the stock is owned by company insiders.

Cigna Group Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.